scispace - formally typeset
S

Steven T. DeKosky

Researcher at University of Florida

Publications -  571
Citations -  77861

Steven T. DeKosky is an academic researcher from University of Florida. The author has contributed to research in topics: Dementia & Alzheimer's disease. The author has an hindex of 124, co-authored 538 publications receiving 70480 citations. Previous affiliations of Steven T. DeKosky include Lexington VA Medical Center & University of Kentucky.

Papers
More filters
Journal ArticleDOI

The Diagnosis of Mild Cognitive Impairment due to Alzheimer’s Disease: Recommendations from the National Institute on Aging-Alzheimer’s Association Workgroups on Diagnostic Guidelines for Alzheimer’s Disease

TL;DR: Criteria for the symptomatic predementia phase of Alzheimer’s disease (AD), referred to in this article as mild cognitive impairment due to AD, has four levels of certainty, depending on the presence and nature of the biomarker findings.
Journal ArticleDOI

Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria

TL;DR: It is proposed that downstream topographical biomarkers of the disease, such as volumetric MRI and fluorodeoxyglucose PET, might better serve in the measurement and monitoring of the course of disease.
Journal ArticleDOI

Practice parameter: Early detection of dementia: Mild cognitive impairment (an evidence-based review) Report of the Quality Standards Subcommittee of the American Academy of Neurology

TL;DR: Screening different groups of elderly individuals in a general or specialty practice would be beneficial in detecting dementia and persons with memory impairment who were not demented were characterized in the literature as having mild cognitive impairment.
Journal ArticleDOI

Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity

TL;DR: The loss of neuronal connectivity, indexed by loss of synapses, predicted the degree of cognitive impairment in the patients who underwent biopsy and indicated a degree of structural change in AD brain not likely to be affected by pharmacotherapy.